- Home
- SIBN vs MLTX Comparison
SIBN vs MLTX Comparison
Compare SIBN & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIBN
- MLTX
- Stock Information
- Founded
- SIBN 2008
- MLTX 2021
- Country
- SIBN United States
- MLTX Switzerland
- Employees
- SIBN N/A
- MLTX N/A
- Industry
- SIBN Medical/Dental Instruments
- MLTX Biotechnology: Pharmaceutical Preparations
- Sector
- SIBN Health Care
- MLTX Health Care
- Exchange
- SIBN Nasdaq
- MLTX Nasdaq
- Market Cap
- SIBN 606.1M
- MLTX 535.3M
- IPO Year
- SIBN 2018
- MLTX N/A
- Fundamental
- Price
- SIBN $15.10
- MLTX $9.40
- Analyst Decision
- SIBN Strong Buy
- MLTX Buy
- Analyst Count
- SIBN 4
- MLTX 9
- Target Price
- SIBN $25.75
- MLTX $37.63
- AVG Volume (30 Days)
- SIBN 455.8K
- MLTX 9.7M
- Earning Date
- SIBN 11-11-2025
- MLTX 11-06-2025
- Dividend Yield
- SIBN N/A
- MLTX N/A
- EPS Growth
- SIBN N/A
- MLTX N/A
- EPS
- SIBN N/A
- MLTX N/A
- Revenue
- SIBN $185,262,000.00
- MLTX N/A
- Revenue This Year
- SIBN $19.96
- MLTX N/A
- Revenue Next Year
- SIBN $16.24
- MLTX N/A
- P/E Ratio
- SIBN N/A
- MLTX N/A
- Revenue Growth
- SIBN 22.93
- MLTX N/A
- 52 Week Low
- SIBN $11.70
- MLTX $5.95
- 52 Week High
- SIBN $20.05
- MLTX $62.75
- Technical
- Relative Strength Index (RSI)
- SIBN 50.88
- MLTX 23.29
- Support Level
- SIBN $14.20
- MLTX $6.56
- Resistance Level
- SIBN $14.76
- MLTX $7.48
- Average True Range (ATR)
- SIBN 0.54
- MLTX 2.22
- MACD
- SIBN 0.09
- MLTX -4.37
- Stochastic Oscillator
- SIBN 91.64
- MLTX 6.07
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.